'Clinical cancer research' diaporamas de présentation

1.62k views • 134 slides

management of low grade glioma

management of low grade glioma. robert r johnson , m.d. department of radiation oncology august 4, 2011. table of contents. background pathological classification m olecular features presentation treatment sequelae future directions. background. slow-growing tumors

1.23k views • 68 slides

Moving from Correlative Science to Predictive Medicine

Moving from Correlative Science to Predictive Medicine. Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://linus.nci.nih.gov/brb. BRB Website brb.nci.nih.gov. Powerpoint presentations and audio files Reprints & Technical Reports BRB-ArrayTools software

805 views • 61 slides

Steps on the Road to Predictive Oncology

Steps on the Road to Predictive Oncology. Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov. Biometric Research Branch Website brb.nci.nih.gov. Powerpoint presentations Reprints BRB-ArrayTools software Sample Size Planning

799 views • 61 slides

Reporting on Scientific Journal Articles

Reporting on Scientific Journal Articles. Jeremy Moore, M.A. Senior Manager, Science Communications American Association for Cancer Research jeremy.moore@aacr.org. Why is Cancer Newsworthy?. Why is Cancer Newsworthy?. Number 1 cause of death, surpassing heart disease in 2010.

669 views • 58 slides

493 views • 36 slides

Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers

Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers. Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov. Validation = Fitness for Intended Use. Intended Uses. Prognostic biomarkers

352 views • 35 slides

Food + Science

Food + Science. Natures Medicines Genetically Modified Organisms (GMO) Molecular Gastronomy The Science Behind Cooking. Jude E. Mathews, Ph.D. Nutraceutical, Phytochemical, Antioxidant.

483 views • 34 slides

Cancer Clinical Trials

Clinical Cancer Research in a Fail-safe Hospital: Mitigating Myths Of Mistrust Steven Wolff, M.D., Meharry Medical College. Cancer Clinical Trials. 20% of adults are eligible for a cancer clinical trial. Less than 3% of adults participate. Even less for minority and medically underserved.

524 views • 30 slides

Cancer Clinical Trials

Clinical Cancer Research in a Fail-safe Hospital: Mitigating Myths Of Mistrust Steven Wolff, M.D., Meharry Medical College. Cancer Clinical Trials. 20% of adults are eligible for a cancer clinical trial. Less than 3% of adults participate. Even less for minority and medically underserved.

475 views • 30 slides

S C A N D I N A V I A N E X C E L L E N C E F R O M L U N D U N I V E R S I T Y

274 views • 19 slides

Hayriye Verda Erk?zan, PhD Lombardi Comprehensive Cancer Center Georgetown University,

Abstract ID: 1773203. THE POTENTIAL BENEFITS AND CAVEATS OF PARP INHIBITORS IN EWING SARCOMA. Hayriye Verda Erk?zan, PhD Lombardi Comprehensive Cancer Center Georgetown University, Washington DC. CTOS Meeting 2013 Nov 2 nd , Saturday 7.45 AM. EWS-FLI1 Protein Partners are

382 views • 16 slides

DEBIRI TACE Patterns and Predictors of Response

DEBIRI TACE Patterns and Predictors of Response. Robert Jones. Declaration Robert Jones is a consultant to Biocompatibles UK LTD. Pathological response to chemotherapy predicts survival. 100 90 80 70 60 50 40 30 20 10 0. Complete response. % survival. Major response. Minor

679 views • 15 slides

Five overarching objectives of the national cancer strategy

The Regional cancercenter of south Sweden - a project for the whole south swedish health region! Established 2010. Five overarching objectives of the national cancer strategy. Reduce the risk of developing cancer Improving the quality of care of patients with cancer

226 views • 15 slides

Using Ensemble Models in the Histological Examination of Tissue Abnormalities

325 views • 14 slides

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter,

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial. Authors: Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Reviewer: Dr. Chris Booth Date posted: December 12 2007.

222 views • 6 slides

Kerbel, R.S., Nature 390: 336, Nov 27, 1997

96 views • 3 slides